Compare Nvidia Corp (NVDA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Smith & Nephew plc — how do they compare? Nvidia Corp trades at $229.48 (market cap $5.57T), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Nvidia Corp is far larger — about 501.8× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and Smith & Nephew plc for 120 Days on average.
| NVDA | SNN | |
|---|---|---|
Market Cap | $5.57T | $11.10B |
Volume | 117,720,595 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $239.27 | $37.17 |
52-Week Low | $165.17 | $26.42 |
Typical Hold Time | 115 Days | 120 Days |
Enterprise Value | $5.54T | $14.13B |
Dividend Yield | 0.43% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $229.25, down 3.42% over the past day amid a broader tech sell-off. The stock maintains a bullish technical signal with strong support near $228 and resistance at $235. Fundamentally, the company reported record revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $339.17 implying significant upside.
NVDA's outlook is supported by robust AI chip demand and accelerating revenue growth, projected to reach $303.0B in 2026. However, risks include heightened competition, potential peak AI spending, and geopolitical tensions affecting market sentiment. The stock presents a compelling growth opportunity but requires monitoring of execution risks and macroeconomic headwinds.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
